Case 3: Individualized Therapy for ET
Experts in essential thrombocythemia discuss approaches to individualizing therapy.
Case 3: Risk Assessment in ET
Dr Stephen Oh discusses risk assessment in patients with essential thrombocythemia.
Case 3: Essential Thrombocythemia (ET)
Stephen Oh, MD, PhD, reviews the case of a 46-year-old female with essential thrombocythemia.
UNITY-NHL Trial in R/R FL and MZL
Experts in hematology/oncology review data from the UNITY-NHL trial and share insights on the sequencing of therapies in R/R FL and MZL.
Role of Umbralisib in R/R FL and MZL
Ian W. Flinn, MD, PhD, and Jason M. Melear, MD, review the tolerability and efficacy of umbralisib in the management of R/R FL and MZL.
Managing Adverse Events of PI3K Inhibitors in R/R FL and MZL
Expert hematologist/oncologists comment on the safety profile of PI3K inhibitors when treating R/R FL and MZL and share their approach to managing associated adverse events.
Role of PI3K Inhibitors in the Management of R/R FL and MZL
Ian W. Flinn, MD, PhD, and Jason M. Melear, MD, review clinical trial data for idelalisib, copanlisib, and duvelisib and discuss their personal experience using these agents for the management of R/R FL and MZL.
Future Directions and Unmet Needs in the Treatment of R/R FL
Looking ahead, Loretta Nastoupil, MD, reviews the future direction and unmet needs in the management of relapsed/refractory follicular lymphoma (R/R FL).
Managing Side Effects of Tazemetostat in R/R FL
Dr Loretta Nastoupil describes best practices for managing the side effects of tazemetostat in patients with R/R FL.
Efficacy of tazemetostat in patients with EZH2m and EZH2wt R/R FL
Loretta Nastoupil, MD, discusses the use of tazemetostat in patients with and without an EZH2m.
Treatment Challenges Beyond the Second-line in R/R FL
Loretta Nastoupil, MD, describes the challenges of selecting treatment beyond the second-line.
Second-line Treatment Options for R/R FL Patients
Considerations for Therapy in R/R FL
A key opinion leader in the treatment of FL provides insight on the decision of whether to add maintenance therapy to the treatment regimen.
First-line Therapy Options in ND Follicular Lymphoma
Loretta Nastoupil, MD, discusses first-line therapy options for patients with newly diagnosed follicular lymphoma (ND FL).
R/R FL Patient Case Review and Impressions
Loretta Nastoupil, MD, describes the role of molecular testing used in risk stratification of patient with FL
Case Presentation: Relapsed/Refractory Follicular Lymphoma
Loretta Nastoupil, MD, reviews the case of a 75-year-old woman with relapsed/refractory follicular lymphoma (R/R FL).
Clinical Trials with Early PI3K Inhibitors in R/R FL and MZL
Expert hematologist/oncologists discuss the use of early PI3K inhibitors in the management of R/R follicular lymphoma (FL) and MZL (marginal zone lymphoma).
Overview of PI3K Inhibition in Lymphoma
Ian W. Flinn, MD, PhD, leads the discussion on the various PI3K isoforms and their role in lymphoma.
Case 2: Considerations for Optimizing Therapy in High Risk MF
Ruben Mesa, MD, and panel discuss considerations for optimizing therapy in high risk myelofibrosis.
Case 2: Efficacy and Safety of Fedratinib in High Risk MF
Experts in myelofibrosis present safety and efficacy data from a clinical trial of fedratinib in patients with high risk myelofibrosis.
Case 2: Safety and Efficacy of Ruxolitinib in High Risk MF
Dr Jamile Shammo presents clinical trial data on the efficacy and safety of ruxolitinib in patients with high risk myelofibrosis.
Case 2: Predictors of Response to Ruxolitinib in High Risk MF
Experts in MPN review data on predictors of response to ruxolitinib in high risk myelofibrosis.
Case 2: Prognostic Models of MF
Jamile Shammo, MD, reviews prognostic models in myelofibrosis.
Case 2: High Risk Myelofibrosis (MF)
Dr Jamile Shammo reviews the case of a 72-year-old man with primary myelofibrosis.
Case 1: Role of Symptomatic Improvement in Overall Outcome in MF
Experts in polycythemia vera review data regarding the role of symptomatic improvement in overall outcome in patients with polycythemia vera.
Case 1: Treatment Approaches for High Risk P. Vera
Prithviraj Bose, MD, and colleagues discuss treatment options for high risk polycythemia vera.
Case 2: REACH3 Trial
The experts discuss the REACH3 trial in steroid-refractory chronic GVHD and what they hope to see in the future of treating chronic GVHD.
Case 2: Steroid-Refractory Chronic GVHD
The experts present and discuss the case of a patient with steroid-refractory chronic GVHD and discuss treatment options.
Case 1: The Role of Ruxolitinib in Steroid-Refractory Acute GVHD
The panelists discuss the role of ruxolitinib steroid-refractory acute GVHD and comment on unmet needs in treating this patient population, including fecal transplants.
Case 1: Ruxolitinib and the REACH2 Trial
Understanding the importance of having a multidisciplinary team in the treatment of acute GVHD, panelists discuss the NCCN Guidelines and REACH2 trial.
